ASSURE Wearable ECG vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, ASSURE Wearable ECG, provides continuous heart rate monitoring and data collection via a wearable device for general cardiac patient management. In contrast, Tool B, EchoGo Amyloidosis, is an AI-powered screening tool specifically designed for the early detection of cardiac amyloidosis by analyzing existing echocardiogram video clips. While both operate within cardiology AI, they address distinct clinical needs: remote patient monitoring versus specific disease detection from diagnostic imaging.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
The ASSURE Wearable ECG is a non-therapeutic device designed for continuous heart rate monitoring and data collection for at-risk cardiac patients. EchoGo Amyloidosis is an AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
The ASSURE Wearable ECG collects continuous heart rate data via a wearable ECG device and SensorFit Garment. EchoGo Amyloidosis analyzes echocardiogram video clips to identify suspected cardiac amyloidosis.
The ASSURE Wearable ECG system includes a wearable device, a mobile application, and a cloud-based remote patient data platform called Kestra CareStation for clinician review. EchoGo Amyloidosis is a cloud-based SaaS model designed for seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7.
The ASSURE Wearable ECG provides automatic episode storage, alert-based notifications, and physiologic trend data from continuous heart rate monitoring. EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis, based on its AI-powered analysis of echocardiographic markers.
For the ASSURE Wearable ECG, pricing details require direct contact with the company. For EchoGo Amyloidosis, specific codes are provided: NTAP Code ICD-10 XXE2X19 for inpatient analysis ($1,000, Medicare-covered) and HCPCS Code C9786, Clinical APC Code 574 for outpatient analysis ($285, covered by Medicare and select commercial insurers).
The ASSURE Wearable ECG features a SensorFit Garment with non-adhesive ECG sensors, the ASSURE Detection Algorithm with Quad Channel Processing, and Adaptive Patient Intelligence for filtering motion artifacts. EchoGo Amyloidosis utilizes AI-powered analysis to assess echocardiographic markers like ventricular volume, cardiac function, and myocardial movement, demonstrating high diagnostic accuracy (85% sensitivity, 93% specificity) across CA subtypes.